Viatris to buy Pacira for $1.65 billion, adding non-opioid pain drugs EXPAREL and ZILRETTA
The $36.50-a-share cash tender offer gives Viatris two U.S. pain products from a company with about $746 million in trailing revenue. Viatris plans to pay mostly from excess cash and close by year-end.

- Value
- $1.65B
- Type
- Acquisition
- Target
- Pacira BioSciences
- Buyer
- Viatris
- Sector
- Pharma
- Announced
- Oct. 8, 2026
Viatris, whose products range from generics to established brands and newer medicines, agreed Oct. 8 to buy Pacira BioSciences for $36.50 a share in cash. The companies said the price values Pacira's equity at about $1.65 billion.
Pacira sells two non-opioid pain products in the U.S. EXPAREL is a liposomal bupivacaine injection for postsurgical pain, and ZILRETTA is an extended-release triamcinolone injection for osteoarthritis knee pain. Pacira brought in about $746 million in total revenue and about $177 million in adjusted EBITDA in the 12 months ended June 30, 2026, according to the announcement.
Why it matters: Viatris is paying for revenue that already exists, not only for a pipeline. Measured against those trailing figures, the equity value is about 2.2 times Pacira's revenue and about 9.3 times its adjusted EBITDA. Viatris described both products as patent-protected and high-margin, and said it plans to lean on its record of extending product lifecycles and holding on to sales after competitors arrive.
The announcement did not state a premium to Pacira's share price.
Viatris will launch a tender offer for all of Pacira's common stock. Any shares not tendered would then be bought at the same $36.50 through a second-step merger. Both boards approved the deal unanimously, and Pacira's board recommends that shareholders tender, the companies said.
To close, Viatris needs a majority of Pacira's outstanding shares tendered and the relevant regulatory waiting period to expire. The companies expect that to happen by the end of 2026. Pacira would then become a wholly owned Viatris subsidiary, and its shares would come off Nasdaq.
Viatris said it will fund the purchase mostly with excess cash and cover the rest with short-term borrowings, which it expects to have minimal effect on its gross leverage ratio. It expects the deal to add to its financial guidance metrics right away.
What Viatris is buying
Beyond the two marketed products, Pacira describes itself as a developer of non-opioid pain therapies. Its most advanced pipeline candidate, PCRX-201, is a gene therapy given locally that is in Phase 2 development for knee osteoarthritis, according to the release.
Scott A. Smith, Viatris' chief executive, called the acquisition "an important step in advancing our strategy to build our innovative medicines business." He said EXPAREL and ZILRETTA are synergistic with the company's fast-acting meloxicam opportunity, and that Pacira brings capabilities in U.S. commercial work, medical affairs, market access and global research and development.
Viatris said it also expects to take the products into select markets through its global infrastructure. Its global centers are in Pittsburgh, Shanghai and Hyderabad, India, according to the release.
Morgan Stanley is Viatris' financial adviser and Cravath, Swaine & Moore its legal adviser, with Centerview Partners also advising. Goldman Sachs is Pacira's exclusive financial adviser, and Ashurst Perkins Coie is its legal adviser.
What comes next
Viatris said it would discuss the deal on its third-quarter earnings call on Nov. 5. The tender offer is the next test: it works only if holders of a majority of Pacira's shares accept $36.50. If they do and the waiting period expires, the companies expect to close before the end of the year.



